Beclomethasone Dipropionate Pharma Grade API is released as a white or almost white crystalline powder for manufacture of tablet, capsule, granule, oral suspension, and injectable suspension dosage forms. The molecular formula C₂₈H₃₇ClO₇ corresponds to a relative molecular mass of 521.05 g/mol; the CAS registry number is 5534-09-8. The API is a synthetic glucocorticoid diester produced by esterification of beclomethasone base, followed by crystallization and, for the micronized and sterile injectable grades, jet milling under nitrogen. Two product models are available: BCDP-PH-M20 for non-sterile oral solid dosage processing and BCDP-PH-S20 for sterile injectable suspension manufacture. The difference between the grades lies in particle-size control, microbial-quality attributes, and packaging configuration, not in the chemical identity of the active moiety.

Pharmacopoeial release is performed against the current European Pharmacopoeia monograph for beclomethasone dipropionate and, when the United States market is specified, against the current USP monograph. The typical release specification includes an assay window of 98.0%–102.0% on the dried basis, loss on drying at ≤0.5% after drying at 105 °C, total related substances at ≤1.0%, and any unspecified impurity at ≤0.10%. Residual solvents are controlled by headspace gas chromatography against ICH Q3C Class 3 limits; acetone and ethanol are commonly limited to ≤5000 ppm each, while Class 1 solvents such as benzene are controlled at ≤2 ppm or the limit specified in the registered dossier. Specific optical rotation according to Ph. Eur. 2.2.7 is controlled within +88.0° to +94.0° at 20 °C in dioxane at a concentration of 10 mg/mL on the dried basis. Infrared absorption spectrophotometry according to Ph. Eur. 2.2.24 is used for identification. The melting point is approximately 212 °C with decomposition and is not used as a release test because decomposition accompanies the melt.

What physical properties govern content uniformity in low-dose oral solid dosage forms?

In tablet and capsule manufacture, the limiting variable is not chemical purity but particle-size distribution and powder flow. Beclomethasone dipropionate is typically formulated at a low dose; a 4 mg strength in a 200 mg tablet core corresponds to 2.0% w/w API. At this concentration, a coarse crystalline powder with a d90 greater than 30 µm can produce superpotent and subpotent units because the number of cohesive API agglomerates per dosage unit is low and segregation occurs during hopper discharge and die filling. The micronized oral grade BCDP-PH-M20 is therefore controlled to a d90 of ≤10 µm and a d50 of ≤5 µm by laser diffraction using Ph. Eur. 2.9.31 or USP <429> with a dry dispersion pressure of 1–3 bar. The larger surface area increases cohesion, so direct compression is usually performed by first preparing a 1:5 or 1:10 trituration with lactose monohydrate or microcrystalline cellulose, followed by high-shear blending at 10–25 rpm for 5–15 min. Content uniformity testing per Ph. Eur. 2.9.40 or USP <905> is used as the release test; the acceptance value is ≤15.0 for a 10-unit sample. For capsules, the same pre-blend is filled using dosator or tamping-pin machines. The practical upper limit for API loading before flow problems becomes limiting is approximately 5.0% w/w; above this value a wet granulation or roller compaction step is normally introduced.

Granulation routes reduce the segregation risk but introduce moisture and heat. Wet granulation with povidone K30 in purified water or an ethanol-water mixture can be used because the API is practically insoluble in water and therefore does not migrate extensively in the wet mass. The granulating fluid should remain below pH 8.0 because the 17,21-dipropionate ester undergoes base-catalyzed hydrolysis. After drying, the granules are milled through a 1.0 mm screen; residual moisture is controlled below the limit for the excipient system, typically 2.0% w/w. Dry granulation by roller compaction is selected when the formulation is moisture-sensitive. Established compaction pressure and ribbon-milling parameters are process-specific and are not transferable without a design-of-experiments study; published data specific to roller-compacted beclomethasone dipropionate granule formulations is limited.

Injectable suspension processing and the microbial-quality boundary

The injectable grade BCDP-PH-S20 is differentiated from the oral grade by bacterial endotoxin control, bioburden, sub-visible particulate matter, and terminal package configuration. Because beclomethasone dipropionate is practically insoluble in water, aqueous injectable products are suspensions, not solutions. The API is processed to a d90 of ≤10 µm and a d50 of 2–4 µm to permit syringeability through a 21-gauge needle and to reduce settling. Contact surfaces are depyrogenated by dry heat at 250 °C for 45 min in accordance with Ph. Eur. 5.1.1. Bacterial endotoxins are determined by LAL assay according to Ph. Eur. 2.6.14; the release limit is assigned in the finished product dossier because the API is not administered directly. When sterile API is required, sterility testing is performed by membrane filtration according to Ph. Eur. 2.6.1 or USP <71>. Sub-visible particulate matter for the finished suspension is tested according to Ph. Eur. 2.9.19 or USP <788>; the API itself is not a finished dosage form and is evaluated after resuspension in the target vehicle. The vehicle commonly contains sodium carboxymethylcellulose, polysorbate 80, benzyl alcohol, and sodium citrate; the API should not be pre-dissolved in ethanol unless the precipitation and particle-growth behavior of the resulting suspension has been characterized.

Terminal moist-heat sterilization of the finished suspension is not universally applicable because the dipropionate ester can hydrolyze under prolonged heat and the suspension may aggregate. Aseptic processing is therefore used for most injectable suspensions of this corticosteroid. The sterile API is added as a dry powder to the filtered, sterile vehicle in a Grade A zone according to EU GMP Annex 1. The filling line must be designed to maintain suspension uniformity during filling; intermittent stirring and recirculation loops are used. The absence of a terminal sterilization step places the burden on component bioburden, depyrogenation, and environmental monitoring. Published data for specific terminal steam-sterilization cycles for beclomethasone dipropionate suspensions is limited; stability studies under ICH Q1A(R2) determine whether a cycle can be considered for a given formulation.

When beclomethasone dipropionate is compared with the base or 17-monopropionate, formulation behavior changes

The dipropionate ester is more lipophilic than beclomethasone base and functions as a prodrug that is hydrolyzed in vivo to the active 17-monopropionate. This difference affects both pharmacology and formulation. The base is more polar, has different crystallinity, and may exhibit different solubility in lipid vehicles. The dipropionate is selected for oral and injectable dosage forms when sustained local or systemic corticosteroid activity is required. It is not interchangeable with beclomethasone base or with other glucocorticoid diesters such as betamethasone 17,21-dipropionate, which has a 9α-fluoro substitution and different receptor-binding kinetics. Manufacturers must use the correct reference standard and system suitability solution because retention times and relative response factors in HPLC methods differ across these related steroids. For pharmaceutical development, the key differentiating attributes are ester substitution, particle-size capability, residual solvent profile, and the elemental impurity profile of the specific manufacturing route.

Elemental impurity control under ICH Q3D is a release requirement

Elemental impurities are controlled according to ICH Q3D using Option 1 limits for oral and injectable products. The manufacturing route does not intentionally use metal catalysts; however, the specification includes Class 1 and Class 2A elements as routine batch-release tests when the regional dossier requires. Limits for lead, cadmium, arsenic, and mercury follow the current USP general chapters and regional guideline values; the exact numerical limits are route-specific and are assigned from the final product risk assessment. Because the injectable route has lower permitted daily exposure limits than the oral route, the injectable grade may require a tighter specification for elemental impurities even though the synthetic route is the same.

The HPLC system for assay and related substances typically uses a C₁₈ column with a mobile phase of acetonitrile, water, and phosphoric acid, with ultraviolet detection at 238 nm. System suitability criteria include a resolution between beclomethasone dipropionate and the 17-monopropionate impurity of not less than 2.0. The exact conditions are defined by the current pharmacopoeial monograph and are not transferable without system suitability verification. Relative retention times are established using the current official reference standard.

Stability studies follow ICH Q1A(R2) at 25 °C/60% RH long term and 40 °C/75% RH accelerated. The primary degradation pathway is hydrolysis of the 17,21-dipropionate ester to beclomethasone 17-monopropionate and beclomethasone base. The rate increases with pH, temperature, and water activity. The micronized powder is electrostatic, and handling at relative humidity above 60% may require nitrogen-blanketed dispensing or pre-drying of excipients to prevent agglomeration. Containers should be re-sealed immediately after sampling because prolonged exposure to ambient air can change powder bed cohesion even though the API is not appreciably hygroscopic.

Strongly alkaline excipients, primary amines, and strong oxidizing agents are incompatible because the 17,21-dipropionate ester is susceptible to base-catalyzed hydrolysis and oxidative degradation. The API should not be blended with unbuffered carbonate salts or hydroxide-based lubricants for extended periods. Magnesium stearate is acceptable when used at 0.5–1.0% w/w and when blending time is minimized because prolonged high-shear mixing of micronized API with magnesium stearate can reduce dissolution through hydrophobic surface coating. These boundaries are evaluated using dissolution testing according to Ph. Eur. 2.9.3 or USP <711>.